Mayne Pharma Group Ltd (FRA:HG6)

Half Year 2025 Mayne Pharma Group Ltd Earnings Call Transcript

Feb 25, 2025 / 10:30 PM GMT

Release Date Price: €4.36 (+4.81%)

Transcript

Key Points

Positve

Revenues increased by 13% to $213.1 million, driven by strong growth in the women's health segment.
Gross margin expanded significantly to 61.4% from 56.3% in the prior corresponding period.
Underlying EBITA rose by 288%, showcasing substantial improvement in profitability.
Positive operating cash flow of $25.9 million from continued operations, a significant turnaround from a negative cash flow in the previous period.
The women's health portfolio showed strong performance with revenues up 30% and direct contribution up 117%.

Negative

Cash and marketable securities decreased to $124.9 million from $149.3 million, impacted by a one-time class action payment.
Revenue from dermatology showed only modest growth of 1%, with competition affecting sales of certain products.
International segment's direct contribution declined due to timing effects of shipments and production schedules.
The acquisition by Cosette Pharmaceuticals may raise concerns about the future strategic direction and independence of Mayne Pharma Group Ltd (MAYNF).
Despite improvements, the company faces ongoing challenges with legacy inventory returns affecting revenue in the women's health segment.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MYX.AX - Mayne Pharma Group Ltd
Half Year 2025 Mayne Pharma Group Ltd Earnings Call
Feb 25, 2025 / 10:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you.

Thank you all for joining. My name is Sean Patrick O'Brien, and I am the CEO and managing director of Maine Pharma.

Today we are here to present our financial results for the six months ended 31 December 2024, namely 1 HY 25.

Joining me on the call this morning is Maine farmer CFO Aaron Gray.

Today our focus will be presenting our first half FY25 results and answering questions about them.

We will briefly cover the recent scheme implementation deed signed with Cosette Pharmaceuticals under which Cosette has agreed to acquire 100% of the shares in Main Pharma by way of a scheme of arrangement for $7.40 cash per share. Further information in relation to this

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.